Viracta Therapeutics

Biotech & Life Sciences · Encinitas, United States · Founded 2016 · IPO 2021

Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients MoreLess

Viracta Therapeutics is a precision oncology company focused on developing innovative therapies for virus-associated malignancies, such as Epstein-Barr Virus (EBV) associated lymphomas. The company operates in the biotechnology and pharmaceutical market, primarily serving patients with viral-associated cancers and other serious diseases. Viracta's business model revolves around the research, development, and commercialization of targeted treatments. The company generates revenue through the sale of its proprietary drugs and potential licensing agreements with other pharmaceutical companies. By leveraging its expertise in oncology and virology, Viracta aims to address unmet medical needs and improve patient outcomes.

Keywords: precision oncology, virus-associated malignancies, EBV, lymphomas, biotechnology, pharmaceutical, targeted treatments, innovative therapies, patient outcomes, virology.

Revenue $2.1M

Total funding $50–100M

Talent graph

Viracta Therapeutics's talent

Book a demo to see the people

Team profiled 11 named & role-tagged

Founders /100 quality score

Key operators 4 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

9 investors on Viracta Therapeutics's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 5 investors entered at this stage

NantKwest

Forward Ventures

Latterell Venture Partners

Wicklow Capital

Shenzhen Salubris Pharmaceuticals

Series B+ 4 investors entered at this stage

Taiwania Capital

Oxford Finance

Standard Treasury

Silicon Valley Bank

Global footprint

Where Viracta Therapeutics has talent and traffic

Workforce by country

🇺🇸 United States · Encinitas HQ

Book a demo for the full country breakdown

Market sentiment

What the market is saying about Viracta Therapeutics

An AI-synthesized read of the highest-engagement posts about Viracta Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Viracta Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles